Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart
18 nov. 2021 16h02 HE
|
Vaxart, Inc.
STANFORD, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- A new Stanford study published in Cell Host and Microbe has demonstrated that VXA-A1.1, an investigational oral tablet flu vaccine under...
Vaxart Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study in Journal of Infectious Diseases
16 nov. 2021 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) announced today the Journal of Infectious Diseases has published complete data from Vaxart’s preclinical...
Vaxart to Participate at Upcoming Conferences
11 nov. 2021 16h01 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and CEO, Dr. Sean Tucker, SVP and Chief Scientific Officer,...
Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results
04 nov. 2021 16h01 HE
|
Vaxart, Inc.
Four clinical trials for COVID-19 and norovirus oral tablet vaccine candidates are currently ongoing Company now operates two GMP manufacturing plants to support rapid clinical advancement of...
Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset
07 juil. 2021 08h00 HE
|
Vaxart, Inc.
Milestone payments up to $130 million and royalties for global Vapendavir sales Vapendavir has demonstrated activity against a broad spectrum of enteroviruses SOUTH SAN FRANCISCO, Calif.,...
Vaxart to Present at the SVB Leerink CybeRx Series: Vaccine Forum
07 juin 2021 09h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by...
Vaxart to Present at the Jefferies Virtual Healthcare Conference
27 mai 2021 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet...
Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults
07 mai 2021 08h00 HE
|
Vaxart, Inc.
Study will evaluate safety and immunogenicity of oral norovirus vaccine in elderly population Norovirus represents a significant unmet need in the elderly — there currently is no approved vaccine ...
Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boosting Regimen Study
04 mai 2021 08h00 HE
|
Vaxart, Inc.
Study will evaluate safety and immunogenicity of multiple distinct dosing regimens of norovirus oral vaccine candidate Norovirus infects 15% of U.S. children under age five every year Study...
New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses
03 mai 2021 17h06 HE
|
Vaxart, Inc.
Vaxart oral vaccine induced higher CD8+ T-Cell responses than those seen with Moderna or Pfizer vaccines in comparative experiment conducted by the Company IgA antibodies triggered in the mucosa,...